Physician profile
Craig Everett Haseman
NPI 1265449649
$10,992.56
in general payments reported to CMS, 2019-2025
57 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $467 · 2021: $771 · 2022: $1,457 · 2023: $2,313 · 2024: $1,985 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,692.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,656.34 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $943.63 | 2019-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $888.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $877.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $804.65 | 2019-2025 | |
| Amgen INC. | $765.53 | 2019-2025 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $759.33 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $424.28 | 2022-2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $380.00 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $324.81 | 2019-2024 | Verquvo, Gardasil 9, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $272.53 | 2019-2025 | Spravato, Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.99 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.65 | 2019-2025 | Jardiance |
| Lundbeck LLC | $189.80 | 2022-2025 | Rexulti |
| Allergan, INC. | $159.96 | 2019-2020 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Haseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.